SGLT2s, GLP-1s may improve mortality, CV event risk after stroke

CHICAGO — Use of an SGLT2 inhibitor or GLP-1 receptor agonist after stroke may improve mortality and lower subsequent risk for heart attack and another stroke, a speaker reported.
Data from Mayo Clinic registry-based analysis to evaluate the impact of SGLT2 inhibitors or GLP-1 receptor agonists on CV event risk and mortality were presented at the American Heart Association Scientific Sessions.
“Patients who had a stroke are at increased risk of a second stroke, heart attack and death. In order to prevent these adverse outcomes, the current guidelines recommend lifestyle medication,

CHICAGO — Use of an SGLT2 inhibitor or GLP-1 receptor agonist after stroke may improve mortality and lower subsequent risk for heart attack and another stroke, a speaker reported.
Data from Mayo Clinic registry-based analysis to evaluate the impact of SGLT2 inhibitors or GLP-1 receptor agonists on CV event risk and mortality were presented at the American Heart Association Scientific Sessions.
“Patients who had a stroke are at increased risk of a second stroke, heart attack and death. In order to prevent these adverse outcomes, the current guidelines recommend lifestyle medication,